Log in

NASDAQ:CTMXCytomX Therapeutics Stock Price, Forecast & News

$8.52
+0.21 (+2.53 %)
(As of 07/10/2020 04:00 PM ET)
Add
Compare
Today's Range
$8.29
Now: $8.52
$8.77
50-Day Range
$7.51
MA: $8.42
$9.42
52-Week Range
$3.60
Now: $8.52
$15.44
Volume404,800 shs
Average Volume596,569 shs
Market Capitalization$391.24 million
P/E RatioN/A
Dividend YieldN/A
Beta0.69
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., and Pfizer Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
Read More
CytomX Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.44 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTMX
CUSIPN/A
Phone650-515-3185

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$57.49 million
Book Value$1.12 per share

Profitability

Net Income$-102,240,000.00

Miscellaneous

Employees137
Market Cap$391.24 million
Next Earnings Date8/5/2020 (Estimated)
OptionableOptionable

Receive CTMX News and Ratings via Email

Sign-up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.

CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions

How has CytomX Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

CytomX Therapeutics' stock was trading at $5.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CTMX shares have increased by 45.1% and is now trading at $8.52. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of CytomX Therapeutics?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CytomX Therapeutics.

When is CytomX Therapeutics' next earnings date?

CytomX Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for CytomX Therapeutics.

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics Inc (NASDAQ:CTMX) posted its earnings results on Thursday, May, 7th. The biotechnology company reported $0.26 EPS for the quarter, beating the consensus estimate of ($0.34) by $0.60. The biotechnology company earned $49.59 million during the quarter, compared to analysts' expectations of $26.93 million. CytomX Therapeutics had a negative return on equity of 99.72% and a negative net margin of 97.83%. View CytomX Therapeutics' earnings history.

What price target have analysts set for CTMX?

9 Wall Street analysts have issued 1-year price targets for CytomX Therapeutics' stock. Their forecasts range from $7.00 to $16.00. On average, they anticipate CytomX Therapeutics' stock price to reach $12.38 in the next year. This suggests a possible upside of 45.2% from the stock's current price. View analysts' price targets for CytomX Therapeutics.

What are Wall Street analysts saying about CytomX Therapeutics stock?

Here are some recent quotes from research analysts about CytomX Therapeutics stock:
  • 1. According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (6/26/2020)
  • 2. Nomura Securities analysts commented, "Progressing IO Probody CX-072—next steps 2H19: CX-072 (PD-L1) in combo with full dose ipi (3mg/kg) is well tolerated—plans for next phase of combo will be revealed in near future. We view undifferentiated pleomorphic sarcoma as offering potentially easier CX-072 combo differentiation vs ipi/PD- (L)1, where this combo has not been tolerated. Monotherapy next steps in 2H19, but based on single-arm expansion data, we still see oppy for monotherapy strategy (e.g., autoimmune disease pts/pts intolerant to PD-1). Solid tumor candidate Ph2 dose, indication: Ph2 registration-worthy? Recall, CTMX saw responses to CX- 2009 in solid-tumor pts including those who failed TROP2 from IMMU. CX- 2009 still in dose refinement, starting at 8mg/kg and using a modified toxicity probability interval (mTPI) design." (8/11/2019)

Has CytomX Therapeutics been receiving favorable news coverage?

Media coverage about CTMX stock has trended neutral on Saturday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. CytomX Therapeutics earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about CytomX Therapeutics.

Are investors shorting CytomX Therapeutics?

CytomX Therapeutics saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 1,680,000 shares, an increase of 40.0% from the June 15th total of 1,200,000 shares. Based on an average trading volume of 698,600 shares, the short-interest ratio is presently 2.4 days. Approximately 3.8% of the shares of the company are sold short. View CytomX Therapeutics' Current Options Chain.

Who are some of CytomX Therapeutics' key competitors?

What other stocks do shareholders of CytomX Therapeutics own?

Who are CytomX Therapeutics' key executives?

CytomX Therapeutics' management team includes the following people:
  • Dr. Sean A. McCarthy, Chairman, CEO & Pres (Age 52)
  • Mr. Debanjan Ray, Sr. VP & CFO (Age 41)
  • Dr. Rachel Wallach Humphrey, Sr. VP & Chief Medical Officer (Age 58)
  • Dr. Hoyoung Huh, Special Advisor to Chief Exec. Officer (Age 50)
  • Dr. W. Michael Kavanaugh, Sr. VP, Chief Scientific Officer and Head of Research & Non-Clinical Devel. (Age 63)

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Diversified Trust Co (0.02%). Company insiders that own CytomX Therapeutics stock include Debanjan Ray, Lloyd A Rowland and Sean A Mccarthy. View institutional ownership trends for CytomX Therapeutics.

Which major investors are buying CytomX Therapeutics stock?

CTMX stock was bought by a variety of institutional investors in the last quarter, including Diversified Trust Co. View insider buying and selling activity for CytomX Therapeutics.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CytomX Therapeutics' stock price today?

One share of CTMX stock can currently be purchased for approximately $8.52.

How big of a company is CytomX Therapeutics?

CytomX Therapeutics has a market capitalization of $391.24 million and generates $57.49 million in revenue each year. The biotechnology company earns $-102,240,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis. CytomX Therapeutics employs 137 workers across the globe.

What is CytomX Therapeutics' official website?

The official website for CytomX Therapeutics is www.cytomx.com.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected]

This page was last updated on 7/11/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.